Surface emerging API suppliers: high YoY trade growth, active FDA Type II DMFs, and clean recent inspections. The qualifiable new-entrant cohort.
Fifteen Indian suppliers cross the emerging-cohort filter in 2025. Harman Finochem tops the list (+250% YoY, $42M, 25 new molecules, NAI plant). Titan Laboratories, Senador Laboratories, and Innova Captab follow with strong USD growth on visible molecule expansion. The cohort represents the qualifiable new-entrant pool below the volume leaders.
| # | Supplier | Region | 2025 USD | YoY growth | Inspection |
|---|---|---|---|---|---|
| 1 | Harman Finochem | IN · Aurangabad | 250 % YoY | $42M · 25 new mols | NAI |
| 2 | Titan Laboratories | IN · Mumbai | 253 % YoY | $21M · 20 new dests | NAI |
| 3 | Senador Laboratories | IN · Hyderabad | 104 % YoY | $48M · 18 new dests | NAI |
| 4 | Innova Captab | IN · Solan | 101 % YoY | $27M · 14 new mols | VAI |
| 5 | ANUH Pharma | IN · Thane | 224 % YoY | $23M · 13 new dests | NAI |
| 6 | HAB Pharmaceuticals | IN · Mumbai | 117 % YoY | $21M · 18 new mols | NAI |
| 7 | Acme Generics | IN · Solan | 106 % YoY | $17M · steady mols | VAI |
| 8 | Aura Lifecare | IN · Hyderabad | 65 % YoY | $14M · 48 new mols | VAI |
Portfolio-wide or molecule-specific. The AI agent pulls the supplier base matching the filter.
YoY growth above the threshold (default 50%), at least one active Type II DMF, and an NAI or VAI-improving inspection class. Suppliers that fail any leg drop out.
Citation-anchored brief with the qualifying cohort, sub-scores per leg, and a chip showing molecule and destination expansion.
A supplier growing 200% YoY but flagged OAI is not emerging, it's drifting. A supplier with clean compliance but flat growth is not emerging, it's stable. The two together is the signal.
Without at least one active Type II DMF, a fast-growing supplier may be ineligible for US-bound API supply. The active-DMF filter ensures the cohort is reachable for an immediate RFQ.
Suppliers expanding molecule footprint or destination footprint are the most likely to have spare commercial bandwidth. The chip surfaces both deltas on the row.
Trade aggregates, DMF register, and inspection feed all refresh weekly. The emerging-cohort filter reruns on every refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query 2025 emerging cohort · counts by composite tier and signal subcategory.
The emerging supplier signal is the qualifiable new-entrant cohort. PharmaDB joins growth momentum to active DMF coverage and inspection class so the cohort is reachable, not speculative. The view rests on company_trade_growth, api_docs, and inspections. Refresh cadence is weekly.
Rising is the directional signal alone (USD growth). Emerging is rising plus active DMF coverage plus clean inspection class. Emerging is the qualifiable subset; rising is the full directional view.
A supplier growing 150% YoY without an active Type II DMF is either selling on non-US lanes (which may not match your needs) or selling intermediates and KSMs (which is a different sourcing motion). The DMF requirement ensures the cohort is reachable for US-bound API supply.
Default 50% YoY on USD exports for suppliers above $5M. The threshold isolates suppliers with non-trivial scale and meaningful trajectory. Buyers can re-cut to 30% or 100% depending on their tolerance for noise vs ambition.
Sometimes. Rapid growth can outpace quality systems; a supplier going from 1 to 100 customers in 18 months may stress their CAPA function. PharmaDB pairs the emerging filter with inspection trajectory tracking, so buyers see whether quality is keeping up with commercial growth.
The headline cohort is Indian by default, because India dominates observable API trade. The same filter applies to Chinese suppliers; PharmaDB labels them in the geography view but they sit on a different observability baseline.
Weekly. Trade aggregates, DMF register, and inspection feed all refresh weekly. The catalog row carries an as-of timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.